This study developed a brucellosis mucosal vaccine (h-tFc-MEV) leveraging FcRn-targeting mechanisms through genetic fusion of human Fc domains with MEV antigens to achieve antigen-FcRn synergy. This evidence concerns the gene FCGRT and brucellosis.